home / stock / cingw / cingw news

CINGW News and Press, Cingulate Inc. Warrants From 06/02/22

Stock Information
Company Name: Cingulate Inc. Warrants
Stock Symbol: CINGW
Market: NASDAQ
Website: cingulate.com
Menu
CINGW CINGW Quote CINGW Short CINGW News CINGW Articles CINGW Message Board
Get CINGW Alerts

News, Short Squeeze, Breakout and More Instantly...
CINGW - Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
CINGW - Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug ...

CINGW - Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...

CINGW - Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...
CINGW - Cingulate Presents at NobleCon18

KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharma...

CINGW - Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements and Time to Approval KANSAS CITY, Kan., March 10, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-s...

CINGW - Cingulate to Present at Aegis Virtual Conference

KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
CINGW - Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...

CINGW - Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors

KANSAS CITY, Kan., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Following its initial public offering last month, Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build...

CINGW - Cingulate Inc. Announces Closing of Initial Public Offering

KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and a...
Previous 10 Next 10